Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Trimethoprim-sulfamethoxazole: An overview

D Byron May, PharmD, BCPS
Section Editor
David C Hooper, MD
Deputy Editor
Jennifer Mitty, MD, MPH


Trimethoprim-sulfamethoxazole (TMP-SMX), also known as co-trimoxazole, is a combination of two antimicrobial agents that act synergistically against a wide variety of bacteria. Although other combinations of sulfonamides are available with trimethoprim, TMP-SMX is by far the most widely used.

This topic will review basic issues related to the clinical use of trimethoprim-sulfamethoxazole. The multiple clinical settings in which this combination may be used are discussed separately on the appropriate topic reviews.


The two components, TMP and SMX, work sequentially to inhibit enzyme systems involved in the bacterial synthesis of tetrahydrofolic acid (THF) [1,2].

SMX is a structural analog of para-aminobenzoic acid (PABA) and competes with PABA to inhibit the synthesis of dihydrofolic acid, an intermediate step in the formation of THF [1,3]. SMX binds to dihydropteroate synthetase which catalyses this reaction [3].

TMP binds to bacterial dihydrofolate reductase (in preference to human dihydrofolate reductase), also preventing the formation of THF [4].


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Wed Mar 04 00:00:00 GMT+00:00 2015.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. Kalkut G. Sulfonamides and trimethoprim. Cancer Invest 1998; 16:612.
  2. Gleckman R, Blagg N, Joubert DW. Trimethoprim: mechanisms of action, antimicrobial activity, bacterial resistance, pharmacokinetics, adverse reactions, and therapeutic indications. Pharmacotherapy 1981; 1:14.
  3. Hong YL, Hossler PA, Calhoun DH, Meshnick SR. Inhibition of recombinant Pneumocystis carinii dihydropteroate synthetase by sulfa drugs. Antimicrob Agents Chemother 1995; 39:1756.
  4. Pattishall KH, Acar J, Burchall JJ, et al. Two distinct types of trimethoprim-resistant dihydrofolate reductase specified by R-plasmids of different compatibility groups. J Biol Chem 1977; 252:2319.
  5. Smilack JD. Trimethoprim-sulfamethoxazole. Mayo Clin Proc 1999; 74:730.
  6. Lundstrom TS, Sobel JD. Vancomycin, trimethoprim-sulfamethoxazole, and rifampin. Infect Dis Clin North Am 1995; 9:747.
  7. Huovinen P. Increases in rates of resistance to trimethoprim. Clin Infect Dis 1997; 24 Suppl 1:S63.
  8. Zhanel GG, Karlowsky JA, Harding GK, et al. A Canadian national surveillance study of urinary tract isolates from outpatients: comparison of the activities of trimethoprim-sulfamethoxazole, ampicillin, mecillinam, nitrofurantoin, and ciprofloxacin. The Canadian Urinary Isolate Study Group. Antimicrob Agents Chemother 2000; 44:1089.
  9. Ma L, Borio L, Masur H, Kovacs JA. Pneumocystis carinii dihydropteroate synthase but not dihydrofolate reductase gene mutations correlate with prior trimethoprim-sulfamethoxazole or dapsone use. J Infect Dis 1999; 180:1969.
  10. Coque TM, Singh KV, Weinstock GM, Murray BE. Characterization of dihydrofolate reductase genes from trimethoprim-susceptible and trimethoprim-resistant strains of Enterococcus faecalis. Antimicrob Agents Chemother 1999; 43:141.
  11. Gibreel A, Sköld O. High-level resistance to trimethoprim in clinical isolates of Campylobacter jejuni by acquisition of foreign genes (dfr1 and dfr9) expressing drug-insensitive dihydrofolate reductases. Antimicrob Agents Chemother 1998; 42:3059.
  12. Mayer KH, Fling ME, Hopkins JD, O'Brien TF. Trimethoprim resistance in multiple genera of Enterobacteriaceae at a U.S. hospital: spread of the type II dihydrofolate reductase gene by a single plasmid. J Infect Dis 1985; 151:783.
  13. Ziha-Zarifi I, Llanes C, Köhler T, et al. In vivo emergence of multidrug-resistant mutants of Pseudomonas aeruginosa overexpressing the active efflux system MexA-MexB-OprM. Antimicrob Agents Chemother 1999; 43:287.
  14. Gleckman R, Gantz NM, Joubert DW. Intravenous sulfamethoxazole-trimethoprim: pharmacokinetics, therapeutic indications, and adverse reactions. Pharmacotherapy 1981; 1:206.
  15. Howe RA, Spencer RC. Cotrimoxazole. Rationale for re-examining its indications for use. Drug Saf 1996; 14:213.
  16. Cunha BA. New uses for older antibiotics. The 'rediscovery' of four beneficial and cost-effective antimicrobials. Postgrad Med 1997; 101:68.
  17. Svedhem A, Iwarson S. Cerebrospinal fluid concentrations of trimethoprim during oral and parenteral treatment. J Antimicrob Chemother 1979; 5:717.
  18. Chin TW, Vandenbroucke A, Fong IW. Pharmacokinetics of trimethoprim-sulfamethoxazole in critically ill and non-critically ill AIDS patients. Antimicrob Agents Chemother 1995; 39:28.
  19. Paap CM, Nahata MC. Clinical use of trimethoprim/sulfamethoxazole during renal dysfunction. DICP 1989; 23:646.
  20. Fishman JA. Treatment of infection due to Pneumocystis carinii. Antimicrob Agents Chemother 1998; 42:1309.
  21. Kovacs JA, Masur H. Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection. N Engl J Med 2000; 342:1416.
  22. Sulfamethoxazole and trimethoprim injection. FDA approved product information. US National Library of Medicine. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=15491 (Accessed on August 09, 2010).
  23. Aronoff, GR, Bennett, WM, Berns, JS, et al. Drug prescribing in renal failure, 5th, American College of Physicians, Philadelphia 2007. p.154.
  24. Nahata MC. Dosage regimens of trimethoprim/sulfamethoxazole (TPM/SMX) in patients with renal dysfunction. Ann Pharmacother 1995; 29:1300.
  25. Mofenson LM, Oleske J, Serchuck L, et al. Treating opportunistic infections among HIV-exposed and infected children: recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America. MMWR Recomm Rep 2004; 53:1.
  26. Jick H, Derby LE. A large population-based follow-up study of trimethoprim-sulfamethoxazole, trimethoprim, and cephalexin for uncommon serious drug toxicity. Pharmacotherapy 1995; 15:428.
  27. Medina I, Mills J, Leoung G, et al. Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone. N Engl J Med 1990; 323:776.
  28. van der Ven AJ, Vree TB, Koopmans PP, van der Meer JW. Adverse reactions to co-trimoxazole in HIV infection: a reappraisal of the glutathione-hydroxylamine hypothesis. J Antimicrob Chemother 1996; 37 Suppl B:55.
  29. Jung AC, Paauw DS. Management of adverse reactions to trimethoprim-sulfamethoxazole in human immunodeficiency virus-infected patients. Arch Intern Med 1994; 154:2402.
  30. Coopman SA, Johnson RA, Platt R, Stern RS. Cutaneous disease and drug reactions in HIV infection. N Engl J Med 1993; 328:1670.
  31. Masters PA, O'Bryan TA, Zurlo J, et al. Trimethoprim-sulfamethoxazole revisited. Arch Intern Med 2003; 163:402.
  32. Hemstreet BA. Antimicrobial-associated renal tubular acidosis. Ann Pharmacother 2004; 38:1031.
  33. Mathews WA, Manint JE, Kleiss J. Trimethoprim-sulfamethoxazole-induced hypoglycemia as a cause of altered mental status in an elderly patient. J Am Board Fam Pract 2000; 13:211.
  34. Markowitz N, Saravolatz LD. Use of trimethoprim-sulfamethoxazole in a glucose-6-phosphate dehydrogenase-deficient population. Rev Infect Dis 1987; 9 Suppl 2:S218.
  35. Johnson MP, Goodwin SD, Shands JW Jr. Trimethoprim-sulfamethoxazole anaphylactoid reactions in patients with AIDS: case reports and literature review. Pharmacotherapy 1990; 10:413.
  36. Greenberg S, Reiser IW, Chou SY, Porush JG. Trimethoprim-sulfamethoxazole induces reversible hyperkalemia. Ann Intern Med 1993; 119:291.
  37. Alappan R, Perazella MA, Buller GK. Hyperkalemia in hospitalized patients treated with trimethoprim-sulfamethoxazole. Ann Intern Med 1996; 124:316.
  38. Perazella MA, Mahnensmith RL. Trimethoprim-sulfamethoxazole: hyperkalemia is an important complication regardless of dose. Clin Nephrol 1996; 46:187.
  39. Fralick M, Macdonald EM, Gomes T, et al. Co-trimoxazole and sudden death in patients receiving inhibitors of renin-angiotensin system: population based study. BMJ 2014; 349:g6196.
  40. Antoniou T, Hollands S, Macdonald EM, et al. Trimethoprim-sulfamethoxazole and risk of sudden death among patients taking spironolactone. CMAJ 2015; 187:E138.
  41. Strom BL, Schinnar R, Apter AJ, et al. Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med 2003; 349:1628.
  42. Gompels MM, Simpson N, Snow M, et al. Desensitization to co-trimoxazole (trimethoprim-sulphamethoxazole) in HIV-infected patients: is patch testing a useful predictor of reaction? J Infect 1999; 38:111.
  43. Cortese LM, Soucy DM, Endy TP. Trimethoprim/sulfamethoxazole desensitization. Ann Pharmacother 1996; 30:184.